EARNINGS

Genentech Inc.'s net income increased 192% to $15.5 million in its second quarter, compared to $5.3 million for the year-ago period. The South San Francisco-based biotechnology firm said the increase was due to the sale of its heart attack drug, Activase, which was approved for sale last November and costs $2,200 per treatment. Product sales for the quarter were $75.1 million, compared to $20 million for the like 1987 period.